AACR Annual Meeting | Conference

Adding Durvalumab/Olaparib to Neoadjuvant Chemo Improves pCR in High-Risk HER2-Negative Breast Cancer

April 28th 2020

The addition of durvalumab (Imfinzi) and olaparib (Lynparza) to neoadjuvant paclitaxel was found to improve pathologic complete response rates compared with paclitaxel alone in patients with high-risk, HER2-negative stage II/III breast cancer.

Poziotinib Shows Mixed Findings in Exon 20-Mutant NSCLC

April 28th 2020

Patients with pretreated non–small cell lung cancer and EGFR exon 20 insertions demonstrated a 68.7% disease control rate while on poziotinib systemic therapy.

Capmatinib Shows Clinical Meaningful Activity and Intracranial Responses in MET Exon 14+ NSCLC

April 28th 2020

Results from the GEOMETRY mono-1 study demonstrated antitumor efficacy of and deep and durable responses with capmatinib in 97 patients with advanced non–small cell lung cancer who harbor MET exon 14 mutations.

Talazoparib Improves QOL, But Not OS in Advanced BRCA1/2+ Breast Cancer

April 28th 2020

Treatment with talazoparib did not demonstrate a statistically significant overall survival benefit in patients with BRCA1/2-mutated metastatic HER2-negative breast cancer.

Atezolizumab Plus Vemurafenib/Cobimetinib Impresses in BRAF V600+ Melanoma

April 28th 2020

Treatment with atezolizumab in combination with vemurafenib and cobimetinib was found to significantly improve progression-free survival and produce durable responses versus vemurafenib and cobimetinib alone in treatment-naïve patients with BRAF V600–mutant advanced melanoma.

Dr. Thirman on the Rationale for Using SNDX-5613 in Acute Leukemias

April 28th 2020

Michael J. Thirman, MD, discusses the clinical rationale for using the investigational agent SNDX-5613 to treat a subtype of acute myeloid leukemia and acute lymphoblastic leukemia.

Dr. Wang-Gillam on Results of a Phase 1 Study With Defactinib in Pancreatic Ductal Adenocarcinoma

April 28th 2020

Andrea Wang-Gillam, MD, PhD, discusses the results of a phase 1 study with defactinib in patients with pancreatic ductal adenocarcinoma.

Continuous Dabrafenib/Trametinib Dosing Improves PFS in BRAF+ Melanoma

April 27th 2020

Continuous dosing with dabrafenib and trametinib improved progression-free survival compared with intermittent dosing in patients with BRAF mutation–positive advanced melanoma.

Dr. Patel on Benefit of Ipilimumab/Nivolumab Combo in High-Grade Neuroendocrine Carcinoma

April 3rd 2019

Sandip Patel, MD, associate professor of medicine at the University of California San Diego School of Medicine, discusses the benefit of the immune checkpoint inhibitor combination of ipilimumab (Yervoy) and nivolumab (Opdivo) in patients with rare, high-grade neuroendocrine tumors.

Surgery Linked With Improved OS in HER2+ Advanced Breast Cancer

April 2nd 2019

Primary tumor surgery for patients with stage IV HER2-positive breast cancer is associated with an improvement in overall survival, according to results of a retrospective cohort review presented at the 2019 AACR Annual Meeting.

Dr. Sequist on Rationale for TATTON Trial in EGFR-Mutant Lung Cancer

April 2nd 2019

Lecia V. Sequist, MD, MPH, thoracic medical oncologist and director of the Center for Innovation in Early Cancer Detection at Massachusetts General Hospital Cancer Center, discusses the rationale for the TATTON trial in non–small cell lung cancer (NSCLC).

LOXO-195 Active After Initial Anti-TRK Failure in Multiple Tumor Types

April 2nd 2019

A third of patients with advanced TRK fusion tumors had objective responses to the second-generation TRK inhibitor LOXO-195 after failure of initial anti-TRK therapy.

Rucaparib Maintenance Shows Early Efficacy in Pancreatic Cancer

April 2nd 2019

Maintenance therapy with rucaparib maintained disease control and was well tolerated in patients with platinum-sensitive, advanced BRCA1/2- or PALB2-mutant pancreatic cancer, according to preliminary interim findings of a single-arm, phase II trial.

Data Support TMB as Marker for Durvalumab Activity in NSCLC

April 2nd 2019

Tumor mutational burden identified patients who obtained a survival benefit with the PD-L1 inhibitor durvalumab, as initial therapy versus chemotherapy for advanced non–small cell lung cancer, even though the primary analysis of the randomized trial showed no difference between treatment groups, according to a new analysis.

Pembrolizumab Shows Promising Antitumor Activity in Pretreated Patients With SCLC

April 2nd 2019

Pembrolizumab (Keytruda) demonstrated promising antitumor activity with durable responses in patients with pretreated advanced small cell lung cancer.

Association Between BMI and Pancreatic Cancer Mortality

April 2nd 2019

Eric J. Jacobs, PhD, cancer epidemiologist and strategic director of pharmacoepidemiology, American Cancer Society, discusses results from a prospective cohort study examining the association between BMI and pancreatic cancer mortality.

Dr. Lipkin on Cancer Prevention Vaccine in Preclinical Model of Lynch Syndrome

April 2nd 2019

Steven M. Lipkin, MD, PhD, the Gladys and Roland Harriman Professor of Medicine, professor of medicine in the Division of Gastroenterology and Hepatology, and vice chair for research in the Weill Department of Medicine at Weill Cornell Medicine; and a geneticist at NewYork-Presbyterian/Weill Cornell Medical Center, discusses a study of a cancer prevention vaccine in a preclinical model of Lynch syndrome during the 2019 AACR Annual Meeting

Gilteritinib Improves OS in Relapsed/Refractory FLT3+ AML

April 1st 2019

Gilteritinib was found to significantly improve overall survival in patients with relapsed/refractory FLT3 mutation–positive acute myeloid leukemia, according to updated findings of the phase III ADMIRAL trial.

Umbralisib Achieves Impressive ORR in Relapsed/Refractory MZL

April 1st 2019

The PI3K-delta inhibitor umbralisib was found to demonstrate an overall response rate of 52% and show an encouraging tolerability profile in patients with relapsed/refractory marginal zone lymphoma, according to findings from a cohort of the phase IIb UNITY-NHL trial.

T-VEC Plus Chemo Hits High pCR Rate in TNBC

April 1st 2019

A majority of patients with large triple-negative breast tumors achieved pathologic complete response when treated with the viral oncolytic talimogene laherparepvec plus neoadjuvant chemotherapy.